التأثير النهائي للتحصين بالكورييني أوفز
على العدوى بجدري الأغنام

عبد المنعم بركات، اسماعيل رضا، عزيز ميخائيل، منيرة نصار
رقيه عثمان

اتضح من هذه الدراسة أن حقن الأغنام بجرعة واحدة من الكورييني أوفز تحتوي
على 87.6٪ من البكتريا والمعامل بالكريستال فيلبس تركز 1/0.05
لله تأثير مناعى مساعد ضد فيروس جدري الأغنام الضرارى. وكانت أعلى درجات
المقاومة لفيروس الجدري بعد 21 يوم من الحقن بالكوريينى حيث هبطت بشدة بعد
ذلك.

كلية الطب البيطرى - جامعة القاهرة
معهد المصل واللقاح - العباسية - القاهرة
THE PROTECTIVE EFFECT OF VACCINATION WITH CORYNE BACTERIUM OVIS ON SHEEP POX INFECTION (With 2 tables)

By
A.A. BARAKAT; L.M. REDA*; A. MICHAEL**; M.L NASSAR**
and ROUKA'IA M. OSMAN**
(Received at 20/1/1986)

SUMMARY

Data presented in this study indicates that the injection of a single dose of $7.5 \times 10^8$ of c.ovis treated with 1 : 750000 crystal violet has a reasonable immuno-potentiating effect in sheep which enables them to show a measurable resistance to experimental inoculation with virulent sheep-pox virus. This c.ovis induced resistance which was highest at 21 days post inoculation and dropped sharply thereafter.

INTRODUCTION

The Egyptian farm animals are subjected to a wide range of stress factors (microbial, parasitic, nutritional, environmental) which in most cases show a side immunosuppressing effect. Thus a search for an immunopotentiating agent seems quite logic in our struggle against infectious diseases of animals.

BCG has already proved its value as an immunopotentiator as shown by international and local experiences (1,2,4).

However, for fear of side-hazzards and interference with T.B- eradication programm, another immuno-stimulant is urgently needed.

More recent studies on crystal violet treated C.ovis have clearly demonstrated its value as a non-specific immunostimulant which can raise the resistance of sheep to artificial infection with potential pathogens. It has even an adjuvant effect when mixed with microbial or inert antigens (3).

The here presented study is a further step in that direction, aiming to throw some light on the non-specific immuno-potentiating capacity of C.ovis as it can be measured in relation of such a dangerous viral disease as sheep pox.

* Fac. of Vet. Med., Cairo Univ.
** Vet. Serum and Vaccine Research Institute, Abbassia, Cairo.

MATERIAL and METHODS

1) Virus:
   a) Modified-live sheep pox virus vaccine Romanian Strain, was grown in susceptible lambs, lyophilized and stored at -20°C until used. The field dose of the reconstituted vaccine was 0.5 ml containing 100 LD₅₀ of infectious viral particles, inoculated intradermally (I/D).
   b) Challenge virus: The Egyptian virulent sheep pox virus, lyophilized and stored at -20°C was used. The challenge dose of reconstituted virulent virus was 0.5 ml containing 1000 LD₅₀ to be inoculated I/D.

2) C.avis:
   This is a local strain isolated from sheep (3). It was used in the form of a suspension containing 7.5x10⁸ bacterial cells/0.2 ml in a diluent containing variable concentration of crystal violet.

3) Sheep:
   Susceptible Barky sheep were selected for this study. They ranged in age from 4-8 months. They had no previous history of sheep-pox or C.avis infection or vaccination.

Determination of resistance of sheep by titration of the virulent sheep pox virus strain in sheep (challenge):

For the determination of the degree of resistance conferred to sheep either due to their specific immunization by sheep pox vaccine or to non-specific protection by C.avis a titration of the virulent virus was done in such sheep. Ten-fold dilutions of the virulent virus were inoculated at both sides of the sheep, each dilution was injected at 3 sites and each site receiving 0.5ml I/D.

EXPERIMENTAL and RESULTS

Experiment I:

Sixteen sheep were divided into 5 groups as follows:
1) Three sheep each inoculated I/D with 1 ml C.avis vaccine suspended in 1 : 100 crystal violet.
2) Three sheep each inoculated I/D with 1 ml C.avis suspended in 1 : 250,000 crystal violet.
3) Three sheep each inoculated I/D with 1 ml C.avis suspended in 1 : 750,000 crystal violet.
4) Three sheep each inoculated I/D with one dose of sheep pox vaccine (0.5 ml) under the tail.
5) Two sheep were inoculated I/D with 1 ml C.avis which was not treated with crystal violet.
6) Two sheep were kept as control without any inoculation. C.avis injection was conducted on the right thigh and the animals were observed for any local reaction.

All sheep were challenged with sheep pox 21 days post vaccination. Results of this experiment are shown in table 1.

It is clear from table 1 that, vaccination of sheep with C.avis had a fair protective effect against challenge (infection) by virulent sheep pox virus. A dose of coryne ovis suspended in 1/750,000 crystal violet showed more protection against sheep pox than the same dose of C.avis suspended in 1/100 or 1/250,000 crystal violet. The log₁₀ reduction in the titre of challenge
VACCINATION WITH CORYNE BACTERIUM OVIS

virus in case of sheep vaccinated with _C. ovis_ suspended in 1/750.000 crystal violet was 4.2 ID<sub>50</sub> /0.5 ml, while in case of sheep receiving the conventional sheep pox vaccine, this reduction reached log<sub>10</sub> 6.5 ID<sub>50</sub>/0.5 ml, with a protection log<sub>10</sub> difference of 2.3 ID<sub>50</sub>/0.5 ml.

Experiment II:

From the results obtained by experiment I, it was found that the best concentration of crystal violet leading to the highest level of resistance against sheep pox infection, is 1/750.000. The bacteria were concentrated 5 times in the treated culture by centrifugation at 3000 r.p.m. for 20 minutes. In this experiment 36 sheep were also used, divided into five groups as follows:

1) Eight sheep, each was inoculated I/D with 0.2 ml _C. ovis_ suspended in 1/750.000 crystal violet (one dose).
2) Eight sheep each inoculated I/D with 0.4 ml _C. ovis_ suspended in 1/750.000 crystal violet (2 doses).
3) Four sheep each inoculated I/D with 0.8 ml _C. ovis_ suspended in 1/750.000 crystal violet (4 doses).
4) Eight sheep each inoculated I/D with one dose of sheep pox vaccine (0.5 ml) under the tail.
5) Eight sheep were kept control without any inoculation. Sheep were kept under close observation for any local reaction. Two sheep from each group were challenged with virulent sheep pox virus 21 days-vaccination; Another 2 sheep from each group were challenged with virulent sheep pox virus 3,6 and 9 months post-vaccination. Decimal dilutions of the virus were inoculated at both sides of the sheep, where each dilution was injected at 3 sites, each receiving 0.5 ml intradermally.

The degree of protection against challenge produced by the different schedules of vaccination was determined both qualitatively and quantitatively. Thus, beside measuring the quantitative reduction in the titre of the challenge virus in vaccinated animals as compared with unvaccinated controls; it was determined also qualitatively the degree of protection by evaluating the decrease in size and duration of the local skin reaction to the intradermally inoculated challenge virus in vaccinated animals as compared with controls. The degree of qualitative protection against challenge with sheep pox virus was categorized as follows:

1) **Complete Protection:**
   Where no fever or dermal reaction occurred.

2) **Good protection:**
   When the diameter of the plaque-like skin and dermal reaction was not greater than one third of that for the control sheep.

3) **Fair protection:**
   In which the dermal reaction was reduced (less than half the diameter of those in the controls).

4) **No protection:**
   When the type and duration of skin reaction were similar to those of the control challenged sheep.

Results of this experiment are shown in table II.

N.B.:
All of the lambs inoculated with 0.8 ml of concentrated C.ovis suspended in 1/750,000 crystal violet (4 doses) died on the 4th day post vaccination and the post-mortem examination revealed toxaemia and jaundice.

Table II indicated that a great difference could be detected between the reaction of group (1) of sheep which were vaccinated by the sheep pox vaccine and those of other C.ovis vaccinated groups. Two doses of C.ovis (0.4 ml) showed more protection against sheep pox infection (4.4 log reduction 21 day post-vaccination) than the 0.2 ml dose (4.2 log reduction 21 day P.V.). By studying the duration of immunity confered by different inocula, it is found that it was nearly lost after 3 months in case of C.ovis inoculated lambs, while it persisted in the group vaccinated by sheep pox vaccine for more than 9 months.

**DISCUSSION**

Previous studies have clearly shown the non specific protective potentials of BCG against bovine and ovine diseases of different aetiology (1, 2, 4).

However, in order to avoid any possible hazzards for BCG application among the livestock, we tried here to draw the attention to the possible use of C.ovis as another candidate in the new-rapidly growing list of immunopotentiating agents.

The here presented study shows clearly that a dose of C.ovis containing $7.5 \times 10^8$ organisms treated with 1/750,000 crystal violet inoculated 21 days before exposure to a titrative challenge with virulent sheep pox strain resulted in a 4.2 log reduction in the titre of that virus as compared to unprotected susceptible controls. This figure although it denotes that treated C.ovis was able to induce some sort of a nonspecific resistance in sheep against infection with the virulent strain of sheep pox, yet this resistance is not as high in its protective effect as the specific immunity confered by the attenuated sheep pox vaccine (a reduction of 6-5 logs in the titre of the virulent virus).

This level of non-specific protection compares well with the results obtained with BCG as immunopotentiation in face of sheep pox (2).

In the second experiment we tried to determine the duration of the non-specific protection produced by C.ovis vaccine treated with 1/750,000 crystal violet when it is given in one and double doses. As shown in table II, it is clear that this non-specific protection was highest 21 days post inoculation with C.ovis, while it steadily decreased and completely vanished by the 9th month post inoculation.

Meanwhile, the specific immuneresponse elicited by the sheep pox vaccine was still clearly demonstrated at the 9th month post vaccination. A slight but non significant difference could be detected between the effect of one or two doses of the C.ovis vaccine. However, it has to be stressed here that 4 doses of that C.ovis-crystal violet vaccine was rapidly fatal to 100% of inoculated sheep, a matter which should draw the attention to the danger of over dosage.

From the above data it could be concluded that the C.ovis crystal violet vaccine beside its protective specific immune response directed against C.ovis infection in sheep, it also produces
VACCINATION WITH CORYNE BACTERIUM OVIS

a certain level of non-specific protection of the inoculated sheep against one of the most dangerous virus diseases of sheep, namely sheep pox. The result without doubt would raise the demand for more comprehensive studies directed to analyse this non-specific protective mechanism on the cellular level and throw some more light on the immuno-potentiating effect of C.ovis.

REFERENCES

Table (I)
The degree of protection conferred by C.ovis vaccine with different concentration of crystal violet against challenge with sheep pox virus

<table>
<thead>
<tr>
<th>Inoculum</th>
<th>log_{10}/virus titre (1/D_{50})</th>
<th>Protection as log_{10} reduction in ID_{50}</th>
<th>C.ovis protection in relation to sheep pox virus</th>
<th>Qualitative protection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sheep pox vacc.</td>
<td>1.8</td>
<td>6.5</td>
<td>0</td>
<td>Complete</td>
</tr>
<tr>
<td>C.ovis + C.v. 1/100</td>
<td>4.7</td>
<td>3.6</td>
<td>2.9</td>
<td>Fair</td>
</tr>
<tr>
<td>C.ovis + C.v. 1/120000</td>
<td>4.8</td>
<td>3.5</td>
<td>3.0</td>
<td>Fair</td>
</tr>
<tr>
<td>C.ovis + C.v. 1/750000</td>
<td>4.1</td>
<td>4.2</td>
<td>2.3</td>
<td>Fair</td>
</tr>
<tr>
<td>Control (virulent sheep pox)</td>
<td>8.3</td>
<td>0</td>
<td>6.5</td>
<td>No</td>
</tr>
</tbody>
</table>

N.B. The two lambs which were inoculated with C.ovis died on the 4th day.

Table (II)
Duration of C.ovis protection against sheep pox virus in relation to sheep pox vaccine

<table>
<thead>
<tr>
<th>Inoculum</th>
<th>Log_{10}/virus titre (ID_{50}) at different time</th>
<th>Protection as log_{10} reduction in ID_{50}/ at different times</th>
<th>C.ovis protection in relation to SPV protection (log difference)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>day 21</td>
<td>3M</td>
<td>6M</td>
</tr>
<tr>
<td>Sheep pox vacc.</td>
<td>1.8</td>
<td>2.1</td>
<td>2.5</td>
</tr>
<tr>
<td>One dose of C.ovis (0.2 ml)</td>
<td>4.1</td>
<td>5.4</td>
<td>6.8</td>
</tr>
<tr>
<td>Two doses of C.ovis (0.4 ml)</td>
<td>3.9</td>
<td>5.0</td>
<td>6.5</td>
</tr>
<tr>
<td>Control</td>
<td>8.3</td>
<td>8.3</td>
<td>8.3</td>
</tr>
</tbody>
</table>

SPV = Sheep pox vaccine.
M = month.